Global Urinary Incontinence Therapeutics Market 2019-2023

The global urinary incontinence therapeutics market is predicted to grow considerably by 2023 fueled by the rising incidences of urinary incontinence in men and women across the globe. Wondering how to make the most of this thriving urinary incontinence therapeutics industry? Technavio’s extensive industry research report offers a detailed insight that will allow you to take full advantage of the opportunities available to you. This study provides an in-depth analysis of the market by considering the evolving demographics and consumer behavior in the global urinary incontinence therapeutics market. It also examines the competitive landscape and some key companies that include Allergan, Astellas Pharma, and Merck.

Let's dissect the latest facts about the urinary incontinence therapeutics industry

The global urinary incontinence therapeutics market is expected to grow at a CAGR of more than 3% during the forecast

Urinary incontinence therapeutics industry growth is expected to accelerate massively over the next five years driven by the robust pipeline for the development of drugs for urinary incontinence treatment. Most of the urinary incontinence therapeutics that are currently in Phase III stage are likely to get approved during the forecast period to augment the growth of the global urinary incontinence therapeutics market. Furthermore, the increasing number of molecules being developed for urinary incontinence treatment will drive the demand for urinary incontinence therapeutics across the period of forecast. Technavio's urinary incontinence therapeutics industry analysis reveals promising markets around the world.

Want a bigger picture? Get a free sample of this report now!

See the complete table of contents and list of exhibits, as well as selected illustrations and example pages from this report.

The Americas will be the largest driver of growth for the global urinary incontinence therapeutics market

More than half of the incremental growth of the global urinary incontinence therapeutics market will be driven by the Americas during the forecast period, while EMEA and APAC are predicted to make sizeable contributions to the market growth. The Americas also held the largest share of around 52% in the global urinary incontinence therapeutics market, followed by EMEA and APAC respectively. However, APAC is forecasted to generate the fastest rate of growth in the global urinary incontinence therapeutics market over the next five years while the Americas will register a higher CAGR than EMEA during the same period.

Get more value with Technavio's subscription platform! Gain easy access to all Technavio's reports, along with on-demand services. Start your 14-day FREE trial

Allergan, Astellas Pharma, and Merck are among the leading vendors in the urinary incontinence therapeutics market

The global urinary incontinence therapeutics market is slated to become reasonably fragmented with the presence of several vendors who offer products for treatment for all types of urinary incontinence. Urinary incontinence is a widespread urological disorder affecting more than 200 million people worldwide and around 17 million people in the US. Many international and regional vendors are vying for their share of the global urinary incontinence therapeutics market, and players must differentiate themselves to gain vital traction over their peers.

This report offers a complete analysis of several companies, including:

• Allergan
• Astellas Pharma
• Merck
• Novartis
• Pfizer

Want to dial in on a specific region or segment? We can help! Our analysts can customize this report to meet your requirements. Get in touch